Compass TherapeuticsCMPX +0.86%23 EV-to-OCF is -4.45 as of Jul. 09, 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Compass Therapeutics ranks better than 54.15% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Compass Therapeutics's Enterprise Value is $236.51 Mil.
Compass Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-53.20 Mil. Therefore, Compass Therapeutics's EV-to-OCF for today is -4.45.
The historical rank and industry rank for Compass Therapeutics's EV-to-OCF or its related term are showing as below:
CMPX'
s EV-to-OCF Range Over the Past 10 Years
Min: -18 Med: -5.23 Max: 0.82
Current: -4.45
During the past 8 years, the highest EV-to-OCF of Compass Therapeutics was 0.82. The lowest was -18.00. And the median was -5.23.
CMPX's EV-to-OCF is ranked better than 54.15% of 1409
companies
in the Biotechnology industry
Industry Median: -3.51
vs CMPX: -4.45
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Compass Therapeutics's PE Ratio (TTM) for today is calculated as:
Compass Therapeutics's share price for today is $2.34.
Compass Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Compass Therapeutics EV-to-OCF Related Terms
Compass Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Compass Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Compass Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's EV-to-OCF falls into.
Compass Therapeutics's current Enterprise Value is $236.51 Mil.
Compass Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics (CMPX) has a EV-to-OCF of -4.45 as of Jul. 09, 2026. According to the industry distribution chart, Compass Therapeutics ranks #646 out of 1409 companies in the Biotechnology industry, placing it in the top 45.8%.
Is Compass Therapeutics' EV-to-OCF too high?
Compass Therapeutics' current EV-to-OCF is -4.45. Based on the distribution chart, Compass Therapeutics ranks #646 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' EV-to-OCF compare to XFOR and LRMR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #646 out of 1409 companies for EV-to-OCF. This puts Compass Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Compass Therapeutics's current EV-to-OCF is -4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current EV-to-OCF of -4.45. The current EV-to-OCF is -4.45. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current EV-to-OCF is -4.45 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score
Get the complete analysis for CMPX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPX has been successfully added to your 
